Great company & recently boosted dividend

25%

Pharmaceutical Product Development is an outsourcing company that helps drug makers arrange clinical trials of new products. North Carolina-based PPD has raised its quarterly dividend 25%, as planned in September, to 12.5 cents a share, from a dime. The respective payment, record and ex dates are Dec. 29, Dec. 15 and Dec. 11. Dividends were initiated in 2005 at a split-adjusted 2.5 cents a share. The stock trades on Nasdaq at roughly half its 52-week high of 49.39 and yields 2.13%. September-quarter diluted earnings per share climbed 34%, to 43 cents, on a 12% revenue advance, to $398.5 million. The backlog totaled $3 billion, up 20%.

Terranova said PPDI has a growth rate 18%, P/E 23 and debt less than 1%. PPDI's Clients include pharmaceutical, biotech, and medical device companies.

25%

Lately, Henwood has added Pharmaceutical Product Development (PPDI), an outsourcing company that helps drug companies put together clinical trials for product testing. (PPDI). - Raymond James

Goldman said it is downgrading Pharmaceutical Product Development (PPDI) to Neutral from Buy based on premium valuation, limited potential for margin expansion, and see catalysts as already reflected in shares. Note 25% gain since added to Goldman's buy list in Feb 2007. Price target lowered to $51 from $55.

Top Five Mid-Cap Stocks
Brittany Umar details some of TheStreet.com Ratings prime picks.

Click here to watch the video.

233%

"With an approaching U.S. presidential election in which health care will be a major issue, the drug makers are clearly in the political cross-hairs. That can only accelerate the flow of new drug testing to the CROs, making Covance and PPD good long-term bets."